Clincosm LogoSign in Get a demo

Clozapine Use Pattern in the Province of Seville

Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (Other)
Overall Status
Completed
CT.gov ID
NCT05083377
Collaborator
(none)
600
Enrollment
1
Location
12
Actual Duration (Months)
50
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

CLOZAPINE USE PATTERN IN THE PROVINCE OF SEVILLE

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Subjects with a diagnosis of schizophrenia (F20 of ICD-10) under treatment with clozapine in the province of Seville. The use of clozapine, variability between centers and treatment modification will be identified.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    600 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Clozapine Use Pattern in the Province of Seville
    Actual Study Start Date :
    Sep 8, 2020
    Actual Primary Completion Date :
    Sep 8, 2021
    Actual Study Completion Date :
    Sep 8, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Patients who have been prescribed clozapine during 2018

    Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.

    Outcome Measures

    Primary Outcome Measures

    1. Identify the pattern of clozapine use in the province of Seville [year 2018]

      Identify the pattern of clozapine use in the province of Seville

    Secondary Outcome Measures

    1. Analyze the variability between centers or professionals [year 2018]

      Analyze the variability between centers or professionals

    2. Analyze the changes in the course of the disease since the prescription of clozapine [year 2018]

      Analyze the changes in the course of the disease since the prescription of clozapine

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.

    Exclusion Criteria:

    • Parkinson's disease

    • Dementia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Universitario Virgen del Rocío Sevilla Spain 41013

    Sponsors and Collaborators

    • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    Investigators

    • Principal Investigator: Benedicto Crespo Facorro, Professor, benedicto.crespo.sspa@juntadeandalucia.es

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
    ClinicalTrials.gov Identifier:
    NCT05083377
    Other Study ID Numbers:
    • CLOZASEV
    First Posted:
    Oct 19, 2021
    Last Update Posted:
    Oct 19, 2021
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
    clozapine
    Additional relevant MeSH terms:
    Schizophrenia

    Study Results

    No Results Posted as of Oct 19, 2021